Ovarian Cancer

Evidence-based overview of Boswellia in ovarian cancer, including taxane-resistance and multidrug-resistance findings

Boswellia has meaningful preclinical interest in ovarian cancer, especially around taxane resistance and multidrug-resistance biology.

Overview

The strongest theme is AKBA's ability to reduce malignancy in taxane-resistant ovarian cancer through effects on drug-resistance machinery.

Key preclinical data

AKBA decreased malignancy in taxol-resistant ovarian cancer models
Reduced P-glycoprotein and LRP-related multidrug-resistance expression
Induced apoptosis in ovarian cancer cell lines
Activity in 3D aggregate models supports relevance to metastatic behaviour

Clinical positioning

This remains a preclinical but valuable area, especially because treatment resistance is such a dominant problem in recurrent ovarian cancer.

References

3-acetyl-11-keto-beta-boswellic acid decreases the malignancy of taxol-resistant human ovarian cancer
https://www.sciencedirect.com/science/article/pii/S0753332219311254

Jump to another Boswellia page

Core pages

Mechanism deep dives

Practical pages

Cancer-type pages

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.